Journal article
Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901
C Cullinane, KL Waldeck, D Binns, E Bogatyreva, DP Bradley, R de Jong, GA McArthur, RJ Hicks
Nuclear Medicine and Biology | ELSEVIER SCIENCE INC | Published : 2014
Abstract
Introduction: The Aurora kinases play a key role in mitosis and have recently been identified as attractive targets for therapeutic intervention in cancer. The aim of this study was therefore to investigate the utility of 3'-[18F]fluoro-3'-deoxythymidine (FLT) and 2-deoxy-2-[18F]fluoro-D-glucose (FDG) for assessment of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901. Methods: Balb/c nude mice bearing HCT116 colorectal xenografts were treated with up to 30. mg/kg TAK 901 or vehicle intravenously twice daily for two days on a weekly cycle. Tumor growth was monitored by calliper measurements and PET imaging was performed at baseline, day 4, 8, 11 and 15. Tumors were harv..
View full abstractGrants
Funding Acknowledgements
This work was supported by a grant received by Grant McArthur and Rodney Hicks from Millennium Pharmaceuticals. Grant McArthur is an uncompensated consultant for Millennium Pharmaceuticals. Daniel Bradley and Ron de Jong are employees of Millennium: The Takeda Oncology Company. The remaining authors have no competing interests.